Who Optimizes SG&A Costs Better? Alkermes plc or Protagonist Therapeutics, Inc.

Optimizing SG&A Costs: A Tale of Two Biopharma Companies

In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Alkermes plc and Protagonist Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Alkermes plc's SG&A expenses have surged by approximately 245%, reflecting their expansive growth strategy. In contrast, Protagonist Therapeutics, Inc. has seen a more modest increase of around 1,700%, albeit from a much smaller base, indicating their rapid scaling efforts.

Alkermes plc, with its established market presence, has consistently maintained higher SG&A expenses, peaking in 2023. Meanwhile, Protagonist Therapeutics, Inc., a smaller player, has shown a steady rise, suggesting strategic investments in growth. This comparison highlights the diverse strategies employed by biopharma companies in managing operational costs, offering valuable insights for investors and industry analysts alike.